Recombinant Human Wnt3a V3 Protein

Name: Recombinant Human Wnt3a V3 Protein
Brand: Beta LifeScience
SKU: BL-2913NP
Availability: InStock

Greater than 95% as determined by reducing SDS-PAGE.

Measured by its ability to induce Topflash reporter activity in HEK293T human embryonic kidney cells.The ED50 for this effect is 71.45 ng/ml.

Collections: Cytokines, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Wnt3a V3 is a Wnt Surrogate Protein and is produced by our Mammalian expression system.
Accession
Synonym	Wnt Surrogate-Fc Fusion Protein; Wnt Surrogate
Gene Background	Wnt-3a is one of 19 vertebrate members of the Wingless-type MMTV integration site (Wnt) family of highly conserved cysteine-rich secreted glycoproteins important for normal developmental processes. WNT signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including bone, liver, skin, stomach, intestine, lung, kidney, central nervous system, mammary gland, taste bud, ovary, cochlea, and vessels among many others. Modulation of WNT signaling pathways has potential for treatment of degenerative diseases and tissue injuries. And they signal through FZD1-10 and LRP5 or 6, two families of receptors. Endogenous WNTs bind to multiple FZDs and are heavily modified posttranslationally, making them difficult to manufacture consistently. WNT surrogate molecules phenocopied endogenous ligand activities in in vitro reporter assays and intestine organoid functional assays. WNT surrogate molecules can be selective for individual FZD or a subfamily of FZDs in combination with LRP5 or LRP6, depending on the binder specificities.
Molecular Mass	58.5kDa
Apmol Mass	66-73kDa, reducing conditions.
Formulation	Supplied as a 0.2 μm filtered solution of 25mM Tris-HCl, 500mM NaCl, pH8.2.
Endotoxin	Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE.
Biological Activity	Biologically active. Please contact us to obtain bioactivity data.
Reconstitution
Storage	Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping	The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.